Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Weighted Average and Diluted) (2019 - 2025)

Agios Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at -$1.85 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 6.32% year-over-year to -$1.85; the TTM value through Dec 2025 reached -$7.11, down 162.7%, while the annual FY2025 figure was -$7.12, 161.17% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.85 in Q4 2025 per AGIO's latest filing, down from -$1.78 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $16.22 in Q3 2024 to a low of -$1.93 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.62, with a median of -$1.6 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 815.79% in 2021, then skyrocketed 1089.02% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.74 in 2021, then surged by 138.51% to $0.67 in 2022, then crashed by 356.72% to -$1.72 in 2023, then fell by 1.16% to -$1.74 in 2024, then fell by 6.32% to -$1.85 in 2025.
  • Per Business Quant, the three most recent readings for AGIO's EPS (Weighted Average and Diluted) are -$1.85 (Q4 2025), -$1.78 (Q3 2025), and -$1.93 (Q2 2025).